Literature DB >> 24798254

Brief review: pain management for cancer survivors: challenges and opportunities.

Shiraz Yazdani1, Salahadin Abdi.   

Abstract

PURPOSE: As the number of cancer survivors continues to increase due to advances in medicine, many cancer survivors remain on their same pain management regimen long after their cancer treatment has been completed. Thus, the purpose of this review is to encourage awareness of the challenges and opportunities of pain management in cancer survivorship. It is our expectation that these patients will be referred to pain medicine specialists so their pain management can be optimized during the period of survivorship and ultimately improve their quality of life. PRINCIPAL
FINDINGS: Cancer and its treatment can cause significant pain which requires multidrug therapy, including strong analgesics such as opioids. Optimal pain management has been shown to improve the quality of life of cancer patients, and that is also true for cancer survivors. Nevertheless, the appropriate use of pain medications, especially opioids, must be re-evaluated and adjusted during treatment as the patient transitions into survivorship care and thereafter. This may otherwise result in unnecessary opioid use or may even lead to abuse. Fortunately, as cancer treatment is completed and the survivorship period begins, pain improves gradually and the need for pain medication should decrease. Unfortunately, some patients continue to take their potent analgesics during the period of survivorship although it may not be necessary. It is a challenge for pain practitioners who do not see these patients early in their disease or in the recovery period. Nevertheless, this challenge presents an opportunity for pain management providers to educate oncologists to refer cancer survivors to pain centres early during the period of their survivorship. Cancer survivors could then receive optimal care and maintain a better quality of life without having to take unnecessary pain medications.
CONCLUSIONS: It is clear that there is a need to improve pain management in cancer patients, particularly in cancer survivors. Pain physicians should play a critical role as part of a multidisciplinary team that cares not only for cancer patients but also for cancer survivors. Optimizing pain management during the cancer survivorship period results in a better quality of life.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24798254     DOI: 10.1007/s12630-014-0170-5

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  6 in total

1.  Losartan, an Angiotensin II Type 1 Receptor Antagonist, Alleviates Mechanical Hyperalgesia in a Rat Model of Chemotherapy-Induced Neuropathic Pain by Inhibiting Inflammatory Cytokines in the Dorsal Root Ganglia.

Authors:  Eunsoo Kim; Seon-Hee Hwang; Hae-Kyu Kim; Salahadin Abdi; Hee Kee Kim
Journal:  Mol Neurobiol       Date:  2019-04-29       Impact factor: 5.590

2.  Cancer Pain Management at Oncology Units: Comparing Knowledge, Attitudes and Perceived Barriers Between Physicians and Nurses.

Authors:  Muhammad Darawad; Malek Khalel Alnajar; Maysoon S Abdalrahim; Aqel Mohammad El-Aqoul
Journal:  J Cancer Educ       Date:  2019-04       Impact factor: 2.037

Review 3.  Advancing breast cancer survivorship among African-American women.

Authors:  Steven S Coughlin; Wonsuk Yoo; Mary S Whitehead; Selina A Smith
Journal:  Breast Cancer Res Treat       Date:  2015-08-25       Impact factor: 4.872

4.  Tempol Ameliorates and Prevents Mechanical Hyperalgesia in a Rat Model of Chemotherapy-Induced Neuropathic Pain.

Authors:  Hee Kee Kim; Seon-Hee Hwang; Salahadin Abdi
Journal:  Front Pharmacol       Date:  2017-01-16       Impact factor: 5.810

5.  Nrf2 activation ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain.

Authors:  Ya-Qun Zhou; Dai-Qiang Liu; Shu-Ping Chen; Nan Chen; Jia Sun; Xiao-Mei Wang; Fei Cao; Yu-Ke Tian; Da-Wei Ye
Journal:  Acta Pharmacol Sin       Date:  2020-03-19       Impact factor: 6.150

6.  Circadian regulation of chemotherapy-induced peripheral neuropathic pain and the underlying transcriptomic landscape.

Authors:  Hee Kee Kim; Sun-Yeul Lee; Nobuya Koike; Eunju Kim; Marvin Wirianto; Mark J Burish; Kazuhiro Yagita; Hyun Kyoung Lee; Zheng Chen; Jin Mo Chung; Salahadin Abdi; Seung-Hee Yoo
Journal:  Sci Rep       Date:  2020-08-14       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.